Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Asylia Therapeutics

Request full access

Committed to transforming scientific advances into medicines for cancer & autoimmune diseases

Houston, United StatesFounded 2019Biotech & Life Sciences

About Asylia Therapeutics

Asylia Therapeutics, Inc. is a development-stage biotechnology company operating from Houston, Texas, focused on creating immunotherapies for cancer and autoimmune diseases. Founded in 2019, the company's scientific foundation stems from research conducted at The University of Texas MD Anderson Cancer Center by its co-founders: Robert Orlowski, M.D., Ph.D., Ronald A. DePinho, M.D., and Richard J. Jones, Ph.D. The company's creation was formalized in October 2020 through an exclusive worldwide license agreement with MD Anderson to develop these therapies. A significant milestone was achieved in May 2021 with the closing of a $14.5 million Series A financing round, led by Sporos Bioventures, to advance its assets toward human clinical trials. This funding also brought in Karthik Radhakrishnan as the founding CEO.

The core of Asylia's business is its drug development platform, which centers on modulating antigen presentation to the immune system. This approach aims to address a key challenge in immunotherapy: the inability of the immune system to recognize many types of cancer. The company's lead product candidate, ASY-77A, is an antibody that targets the extracellular form of Heat Shock Protein 70 (HSP70). This protein is crucial for delivering tumor antigens to dendritic cells, which then activate T-cells to attack and kill cancer cells. By enhancing this natural process, ASY-77A is designed to convert immunologically "cold" tumors, which are unresponsive to many treatments, into "hot" tumors that the immune system can effectively target. Pre-clinical models have shown ASY-77A to be effective against a variety of solid tumors, including breast and colon cancer, as well as blood-related cancers like multiple myeloma.

Asylia's business model is that of a privately held, venture-backed biotechnology firm in the pre-clinical trial stage. Its primary focus is on research and development to bring its novel antibody drugs through clinical trials and eventually to market. The company targets the oncology and autoimmune disease markets, with potential applications in conditions like lupus. Revenue generation is not yet a factor, as the company is concentrated on advancing its therapeutic pipeline. Its financial strategy has involved securing grants, including $3 million from the Cancer Prevention and Research Institute of Texas, and venture capital funding.

Source: Dealroom company data

At a glance

Status
Operational
Employees
3
Open positions
None listed
Dealroom signal
52.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC May 2021 $15M $58M Sporos Bioventures —
SPINOUT✓Other financing Jan 2019 $0 — University of Texas Health Science Center at Houston · MD Anderson Cancer Center —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Asylia Therapeutics website traffic

Latest recorded traffic for Asylia Therapeutics is 640 monthly website visits, down 64.4% over the last three months. Asylia Therapeutics's team grew 0% over the past year.

Latest monthly visits640 3-month web change-64.4% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Asylia Therapeutics in the Houston ecosystem

Live from Dealroom

The Asylia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Sporos Bioventures

Other known investors2 additional known investors

  • MD Anderson Cancer Center
  • University of Texas Health Science Center at Houston
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Houston HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Asylia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Asylia Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.